Loading...
Explore Speciality Medicines SME IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Speciality Medicines Limited, incorporated in 2021, is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.
Core Business: Marketing and distribution of finished pharmaceutical formulations.
Main Products/Services: The company's portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets. They also offer human and animal medicines, vaccines, and plasma products.
Industry Focus: High-cost oral and injectable medications used to treat complex chronic conditions, with a particular focus on therapeutic areas.
Key Highlights:
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 20 Mar - 24 Mar 2026 |
| IPO Price Band | ₹117 - ₹124 per share |
| Fresh Issue | 27.28 Cr |
| Offer For Sale | NIL |
| Total IPO Size | 27.28 Cr |
| Face Value | 10 |
| Listing On | BSE SME |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 20 Mar 2026 |
| IPO Closing Date | 24 Mar 2026 |
| Basis Of Allotment | 25 Mar 2026 |
| Refunds | 27 Mar 2026 |
| Demat Transfer | 27 Mar 2026 |
| IPO Listing Date | 30 Mar 2026 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2024 | 31 Mar 2025 | 31 Oct 2025 |
|---|---|---|---|
| Assets | 22.68 | 39.98 | 45.57 |
| Total Income | 27.66 | 58.54 | 36.93 |
| Profit After Tax | 2.93 | 8.61 | 6.06 |
| EBITDA | 5.26 | 9.09 | 6.51 |
| NET Worth | 15.06 | 30.42 | 36.47 |
| Reserves and Surplus | 9.95 | 23.98 | 30.04 |
| Total Borrowing | 2.86 | 5.05 | 4.81 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Speciality Medicines Ltd. | 8.79 | 14.1 | 28.42% | 47.26 |
| Mono Pharmacare Ltd. | 7.49 | 1.75 | 9.9% | 17.66 |
| Trident Lifeline Ltd. | 27 | 10.22 | 18.23% | 56.05 |
| Remus Pharmaceuticals Ltd. | 10.41 | 65.21 | 15.02% | 434.25 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not more than 2% of the Net Issue |
| Non-Institutional Investor (NII/HNI) | Not less than 49% of Net Issue |
| Retail Individual Investor (RII) | Not less than 49% of Net Issue |
As the issue has not yet opened, subscription data is unavailable. However, you can view subscriptions for other ongoing issues here.
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat –380051
Website:https://www.specialitymedicine.com/
Phone:+91 22 4604 5344
Email:investors.grievances@specialitymedicine.com